Under the Poerwork Reduction Act of 1995.  TRANSMITTAL FORM  (to be used for all correspondence after initial in the correspondence after initial init	Ad Unit	Approved for use through 04/30/2003. OMB 0651-0031 atent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ection of information unless it displays a valid OMB control number.  10/658,164  September 9, 2003  RLSchapaugh  1641  not yet assigned  00373.US1
	ENCLOSURES (Check all	that apply)
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer  Request for Refund CD, Number of CD(s)  Remarks	
CICNA	FUDE OF ADDUCANT ATTO	DNEY OD ACENT
Firm or Individual name Pharmacia & Upjohn Signature  Date Ftb. 27	Company, John H. Engelmann (  1004  ERTIFICATE OF TRANSMISSI	28,075)

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

the date shown below.		
Typed or printed name	Julie K. Lyons	
Signature	water V I am	Date Fibruary 27, 20

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<del></del>											
			Atty. Docket No.			Serial No.					
				00373.US1			10/658,164				
LIST	FEE	ERENCES CITE  See several sheets if ne	ED BY APPLICANT								
			•	Applicant	Schapaugl	n et al.	L		<del></del>		
MAR 0 3 2004 U.S. PA			Filing Date	September	9, 2003	1641					
VE 1	RABEUN		U.S.	PATENT DOCUM	ENTS	·	-				
Examiner Initial		Document Number	Date	Name		Class	Subclass	Filing I			
<u>-</u>	AA	5,721,359	Feb. 24, 1998	Dunn et al.		540	227				
<del></del>						1					
			<u> </u>		·			<u> </u>			
		<u> </u>				<u> </u>					
	T	Document	Date	GN PATENT DOCU	JMENTS	Class	Subclass				
		Number	Date	Country		Class	Subclass	Translation			
	<u> </u>							Yes	No		
	AB	JP 05-249097	Sept 28, 1993	Japan .		G01N	33/15	· X			
						7					
,	<b>†</b>										
	<u> </u>	· · · · · · · · · · · · · · · · · · ·		-					<u> </u>		
									+		
	<u></u>		OWITED DDIOD ADM	7 1 1: 4 1) 5:1		1			<u>.</u>		
	140		OTHER PRIOR ART					<del></del>	· 		
· · · · · · · · · · · · · · · · · · ·	AC	Andonaegue et al., Drug Development and Industrial Pharmacy, 25(11), 1199-1203 (1999)									
<u>.</u> .	· AD	Conti et al., Dru	Conti et al., Drug Development and Industrial Pharmacy, 21(10), 1223-1233 (1995)								
	AE <sub>.</sub>	Machida et al. C	Chem. Pharm. Bull., 3	4(6), 2637-2641, (19	986)				<u>.                                    </u>		
	AF	G. K. Shiu, Drug Information Journal, 30, 1045-1054, (1996)									
	AG	Takahashi et al., Chem. Pharm. Bull., 42(8), 1672-1675, (1994)									
				•					•		
<del></del>				-	<b></b>						
	<u> </u>								· · · · · · · · · · · · · · · · · · ·		
Examiner	<u></u>	<del></del> ;		Date Considere	ed .						